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The latent membrane protein 1 (LMP1) of Epstein–Barr virus (EBV) transforms cells activating signal transduction pathways such as NF-κB,
PI3-kinase, or c-Jun N-terminal kinase (JNK). Here, we investigated the functional role of the LMP1-induced JNK pathway in cell transformation.
Expression of a novel dominant-negative JNK1 allele caused a block of proliferation in LMP1-transformed Rat1 fibroblasts. The JNK-specific
inhibitor SP600125 reproduced this effect in Rat1-LMP1 cells and efficiently interfered with proliferation of EBV-transformed lymphoblastoid
cells (LCLs). Inhibition of the LMP1-induced JNK pathway in LCLs caused the downregulation of c-Jun and Cdc2, the essential G2/M cell cycle
kinase, which was accompanied by a cell cycle arrest of LCLs at G2/M phase transition. Moreover, SP600125 retarded tumor growth of LCLs in a
xenograft model in SCID mice. Our data support a critical role of the LMP1-induced JNK pathway for proliferation of LMP1-transformed cells
and characterize JNK as a potential target for intervention against EBV-induced malignancies.
© 2007 Elsevier Inc. All rights reserved.Keywords: Epstein–Barr virus (EBV); Latent membrane protein 1 (LMP1); c-Jun N-terminal kinase (JNK); JNK inhibitor; Transformation; Cell cycle; TumorIntroduction
The latent membrane protein 1 (LMP1) is the primary
oncogene of the gammaherpesvirus EBV, which is expressed in
many EBV-associated human malignancies such as Hodgkin's
lymphoma, nasopharyngeal carcinoma, or post-transplant lym-
phoproliferative disorders (PTLD) (Young and Rickinson,
2004). EBV infects primary human B-cells transforming them
into lymphoblastoid cell lines (LCLs) (Kuppers, 2003; Thorley-
Lawson, 2001; Young and Rickinson, 2004). LMP1 is essential
for B-cell growth transformation by the virus and transforms
rodent fibroblasts in culture (Kaye et al., 1993; Kilger et al.,
1998; Wang et al., 1985). Tissue-specific expression of LMP1 in
B-cells of transgenic mice results in the development of B-cell
lymphomas (Kulwichit et al., 1998). Expressed in the epithe-
lium, LMP1 induces hyperplasia (Stevenson et al., 2005).
The LMP1 molecule consists of 386 amino acids. Six
transmembrane helices connect a short cytoplasmic N-terminus
with a C-terminal cytoplasmic signaling domain of 200 amino⁎ Corresponding author. Fax: +49 89 7099 225.
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doi:10.1016/j.virol.2007.09.044acids (Kieser, 2007). LMP1 acts like a constitutively active
pseudo-receptor (Floettmann and Rowe, 1997; Gires et al.,
1997). Two subdomains within the signaling domain are
required for B-cell transformation and the induction of signal
transduction, CTAR1 (amino acids 194–231) and CTAR2
(amino acids 351–386) (Brinkmann and Schulz, 2006; Kieser,
2007). Inactivation of either domain by deletion or mutation also
affects LMP1's potential to transform Rat1 fibroblasts (He et al.,
2000; Mainou et al., 2005; Moorthy and Thorley-Lawson,
1993). The P(204)xQxTmotif of CTAR1 recruits tumor necrosis
factor receptor-associated factors (TRAFs) 1, 2, 3, and 5,
whereas tyrosines 384 and 385 of CTAR2 are essential for the
direct interaction with the death domain protein TRADD
(Kieser, 2007). In addition, TRAF6 acts a critical signaling
mediator of LMP1 upon indirect interaction with the LMP1
signaling complex (Luftig et al., 2003; Schultheiss et al., 2001;
Wan et al., 2004).
CTAR1 activates p38 mitogen-activated protein kinase
(MAPK), the phosphatidylinositol 3-kinase (PI3-kinase)/Akt
pathway, and the alternative NF-κB pathway which is mediated
through p100 processing. CTAR2 induces classical I-κB-
dependent NF-κB signaling and critically contributes to p38
247H. Kutz et al. / Virology 371 (2008) 246–256MAPK activation by LMP1 (Kieser, 2007). The c-Jun N-
terminal kinase (JNK) pathway is another major route of LMP1
signaling which is triggered by the CTAR2 domain and leads to
the activation of the transcription factor AP1. In addition, it has
been reported that CTAR1 can also contribute to JNK activation
in a panel of cell lines if TRAF1 is expressed (Eliopoulos et al.,
2003). JNK activation by LMP1 involves the signaling
mediators TRAF3, TRAF6 and, further downstream, TAK1
and TAB1 (Eliopoulos and Young, 1998; Kieser et al., 1997;
Kieser et al., 1999; Wan et al., 2004; Xie et al., 2004). JNK
phosphorylates the N-terminal transactivation domain of the
AP1 component c-Jun at serines 63 and 73 enhancing c-Jun-
dependent transcription (Smeal et al., 1991). Accordingly,
LMP1 induces the transcriptional potential of c-Jun (Kieser
et al., 1997).
Previous studies have shown that the NF-κB pathway plays
an essential role in B-cell transformation by EBVupregulating a
panel of anti-apoptotic genes, B-cell activation markers and
cytokines (Cahir McFarland et al., 1999; Kieser, 2007). The
PI3-kinase pathway promotes cell survival and contributes to
morphological transformation and colony formation of LMP1-
transformed Rat1 cells in soft agar (Dawson et al., 2003;
Mainou et al., 2005). p38 MAPK is involved in cytokine
induction by LMP1 (Eliopoulos et al., 1999; Vockerodt et al.,
2001). In contrast, the role of the LMP1-induced JNK pathway
in cell transformation has not been addressed so far. Depending
on the cell type and stimulus, the JNK pathway can mediate a
wide variety of cellular processes ranging from stress response
and cell death to cell proliferation and transformation (Karin
and Gallagher, 2005).
Here, we demonstrated that inhibition of JNK signaling
causes a proliferative block in LMP1-transformed Rat1 cells
and EBV-transformed human B-cells. We found that the LMP1-
induced JNK pathway is required for efficient progression of
lymphoblastoid cells through the cell cycle, and for maintainingFig. 1. JNK mutants harboring a D169A mutation are kinase-dead and block AP1
HEK293 cells were transfected with 1 μg of the indicated JNK constructs and 1 μg of
domain including CTAR1 and CTAR2. HA-tagged JNK proteins were immunopreci
assays in HEK293 and Rat1 cells. HEK293 cells were transfected with 1 μg of the in
with 1 μg of pRTU14 together with 4 μg of pRK5 or pRK5-HA-JNK1(D169A) and 2
AP1 reporter assays were performed. Given data are mean values with standard devexpression of c-Jun and the G2/M cell cycle kinase Cdc2. In
vivo, inhibition of JNK by the JNK-specific inhibitor SP600125
resulted in a reduced tumor growth of lymphoblastoid cells in
severe combined immunodeficiency (SCID) mice, identifying
the JNK pathway as a potential target for the intervention
against EBV-induced malignancies.
Results
Dominant-negative JNK1(D169A) interferes with proliferation
of LMP1-transformed Rat1 cells
The aim of this study was to characterize the functional role
of the JNK pathway in LMP1-induced cell transformation. The
PxQxT site of CTAR1 and a single motif within CTAR2
including residue Tyr 384 are responsible for LMP1 activation
of NF-κB, JNK and p38 MAPK (Kieser, 2007). Therefore, it is
impossible to generate LMP1 mutants which are defective in
JNK signaling without affecting other LMP1-induced path-
ways. For this reason, we chose to specifically interfere with
JNK signaling downstream of LMP1 by expressing a dominant-
negative JNK allele in LMP1-transformed cells. To generate
efficient dominant-negative JNK mutants lacking intrinsic
kinase activity, we inactivated the kinase domain of JNK1
and JNK2 by mutating the conserved D(169)FG motif which is
essential for Mg-ATP binding by many kinases. To demonstrate
that JNK(D169A) mutants had lost their enzymatic activity,
HA-tagged JNK1(D169A) and JNK2(D169A) were expressed
in HEK293 cells in the absence or presence of functional LMP1
as a JNK inducer. Subsequent in vitro kinase assays verified that
both JNK(D169A) mutants were indeed fully kinase-dead, even
if expressed in the presence of LMP1 (Fig. 1A).
To test if coexpression of JNK(D169A) interfered with the
LMP1-induced endogenous JNK pathway, AP1 reporter gene
assays were performed in HEK293 and Rat1 cells (Fig. 1B).activation by LMP1 in a dominant-negative fashion. (A) JNK kinase assays.
pSV-LMP1 or pSV-LMP1Δ194–386 which lacks the complete LMP1 signaling
pitated and tested for their ability to phosphorylate GST-c-Jun. (B) AP1 reporter
dicated constructs and the AP1 reporter pRTU14. Rat1 cells were electroporated
μg of pSV-LMP1 or mock DNA. 24 h post transfection, the cells were lysed and
iations of five (HEK293) or three (Rat1) experiments, respectively.
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complexes which are activated by LMP1 through JNK-
dependent phosphorylation of the AP1 component c-Jun
(Kieser et al., 1997). Overexpressed inactive JNK(D169A)
was expected to displace endogenous wildtype JNK and, thus,
to inhibit downstream signaling of JNK to AP1. Both, JNK1
(D169A) and JNK2(D169A) completely blocked AP1 induc-
tion by LMP1 demonstrating that JNK(D169A) mutants are
suitable tools to efficiently interfere with LMP1-induced JNK
signaling in a dominant-negative fashion (Fig. 1B). We decided
to continue our experiments with JNK1(D169A) because JNK1
and JNK2 are activated by the same upstream kinases, MKK4
(also known as SEK1) and MKK7, and both JNK(D169A)
mutants blocked AP1 induction by LMP1 equally well.Fig. 2. The retroviral transfer of JNK1(D169A) retards proliferation of LMP1-transf
WPRE,Woodchuck hepatitis virus post-transcriptional regulatory element. (B) Efficie
day 4 post infection with 3054-HA-JNK1(D169A) or empty retrovirus. Left column
(D169A) and LMP1. Aliquots of the cells shown in panel B were lysed, HA-JNK1(D1
antibody (upper panels). Lower panels, LMP1 expression. (D) Effect of HA-JNK1(D
cultures shown in panel B were plated at low cell density and photographed 1 weekNext, the role of the JNK pathway in transforming Rat1
fibroblasts by LMP1was investigated. Several attempts to stably
express JNK1(D169A) in LMP1-transformed Rat1 cells did not
result in the outgrowth of cell clones, whereas stable expression
of JNK1(D169A) was unproblematic in parental Rat1 cells (data
not shown). To trace single cell fate immediately after trans-
duction of JNK(D169A), Rat1 wildtype and Rat1-LMP1 cells
were infected with a retrovirus expressing hemagglutinin (HA)-
tagged JNK1(D169A) from a bicistronic mRNA together with
green fluorescent protein (GFP) as a phenotypic marker gene
(Fig. 2A). Green fluorescence of cells infected with the 3054-
HA-JNK1(D169A) retrovirus indicated expression of HA-JNK1
(D169A), whereas cells infected with empty control virus
expressed GFP only (Fig. 2B). Transduced HA-JNK1(D169A)ormed Rat1 cells. (A) Retroviral constructs. IRES, internal ribosomal entry site;
ncy of retroviral transduction. Cultures of Rat1 wildtype and Rat1-LMP1 cells at
, phase contrast; right column, GFP fluorescence. (C) Expression of HA-JNK1
69A) was immunoprecipitated and detected on immunoblots by the JNK1 (C17)
169A) expression on cell proliferation scored as single cell colony growth. Bulk
after seeding. Upper panels, phase contrast; lower panels, GFP fluorescence.
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HA-JNK1(D169A) expression did not cause significant cell
death in Rat1-LMP1 cells, as detected by comparable numbers
of viable green cells in Rat1-LMP1 cultures freshly infected
with 3054-HA-JNK1(D169A) or empty virus (Fig. 2B). To test
whether proliferation of LMP1-transformed Rat1 cells was
affected by downregulation of the JNK pathway, we seeded
retrovirally infected cells at low cell densities in 15 cm tissue
culture dishes and monitored the outgrowth of green fluorescent
single cell colonies. Colony formation of Rat1 wildtype cells
was not influenced by HA-JNK1(D169A) expression but
HA-JNK1(D169A) strongly retarded colony growth of Rat1-
LMP1 cells as compared to all controls (Fig. 2D). Due to this
phenotype of JNK1(D169A) expression in Rat1-LMP1 cells,
further expansion of the cell clones was not feasible. This result
showed that a functional JNK pathway is required for pro-
liferation of LMP1-transformed but not parental Rat1 cells and
explained our previous problems to establish Rat1 cell lines
expressing both LMP1 and JNK1(D169A).
Block of proliferation induced by a JNK-selective inhibitor in
Rat1-LMP1 cells
The JNK inhibitor SP600125 (Bennett et al., 2001) was used
to validate our previous results with a different method of JNKFig. 3. The JNK inhibitor SP600125 blocks proliferation and soft agar growth of LMP1-
of c-Jun in Rat1-LMP1 cells. Cells were treated with 1‰ DMSO (D) or 20 μM SP600
immunoblotting. The non-specific band (n.s.) confirmed equal loading. (B)MTTassays.
the presence of 1‰ DMSO or 20 μM SP600125. Data are mean values with standard d
agar in the presence of 1‰DMSOor 20μMSP600125. Photoswere taken at day 11 afte
the inhibitor. At day 0, 2×103 Rat1-LMP1 cellswere seeded perwell of a 96-well plate. S
controls were kept in the presence of DMSO throughout the experiment. Data are meainhibition and to exclude possible clonal effects. SP600125 is
selective towards JNK and does not inhibit other MAPKinases,
cyclin-dependent kinases (CDKs) or LMP1-induced pathways
at concentrations of 10 to 20 μM in the cell culture medium (Du
et al., 2004; Gururajan et al., 2005) (see: Fig. 6C). SP600125
diminished LMP1-induced levels of phosphorylated c-Jun, the
direct readout of JNK activity, to background in Rat1 cells
(Fig. 3A). JNK inhibition by SP600125 resulted in a strongly
reduced proliferation of Rat1-LMP1 cells (Fig. 3B). In contrast,
Rat1 wildtype cells remained unaffected by SP600125 treat-
ment, excluding unspecific effects of the inhibitor on Rat1
proliferation (Fig. 3B).
LMP1-expressing Rat1 cells did not proliferate faster than
parental Rat1 cells. However, Rat1-LMP1 cells continued to
divide when they had reached confluency (between day 3 and
4), whereas non-transformed Rat1 cells almost ceased to prolif-
erate at this state (Fig. 3B). Another hallmark of Rat1 trans-
formation by LMP1 is the induction of anchorage-independent
growth, detected as colony formation in soft agar (Wang et al.,
1985). Because SP600125 blocked proliferation of Rat1-LMP1
cells in monolayer cultures, it was tempting to speculate that
colony growth of LMP1-transformed cells in soft agar would be
affected by JNK inhibition as well. In fact, SP600125 treatment
strongly interfered with soft agar growth of Rat1-LMP1 cells
(Fig. 3C).transformed Rat1 cells. (A) SP600125 inhibits the LMP1-induced phosphorylation
125 (SP), or kept untreated (w/o) for 24 h. c-Jun phosphorylation was analyzed by
At day 0, 5×103 Rat1 or Rat1-LMP1 cells were seeded perwell of a 96-well plate in
eviations of four experiments. (C) Soft agar assays. Cells were seeded in 0.4% soft
r seeding. (D) Release of the SP600125-induced proliferative block after removal of
P600125was added and subsequently removed at the indicated time points. DMSO
n values with standard deviations of three experiments.
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bition was not due to apoptosis induction. Annexin V-staining of
the cells revealed that Rat1-LMP1 cells treated with SP600125
had a similar apoptosis rate as untreated cells (data not shown).
Thus, the proliferative block imposed on Rat1-LMP1 cells by
JNK inhibition was reversible. Removal of the inhibitor after
4 days of incubation released the proliferative block and Rat1-
LMP1 cells re-entered the proliferative program (Fig. 3D).
CTAR1 and CTAR2 of LMP1 co-operate to induce JNK in Rat1
cells
A previous report showed that the JNK-inducing capacity of
CTAR1 is dependent on the tested cell type (Eliopoulos et al.,
2003). We performed HA-JNK1 kinase assays to dissect the
potential contributions of the TRAF interaction domain P(204)
xQxT within CTAR1 and Y384 within CTAR2 to JNK
induction by LMP1 in Rat1 cells (Fig. 4A). Wildtype LMP1
induced JNK1 to a level of 6.0-fold activity compared to
LMP1Δ194–386 which lacks the entire LMP1 signaling
domain. Interestingly, CTAR1 and CTAR2 almost equally
contribute to JNK activation in Rat1 cells. LMP1(PQT→AAA)
harboring a mutated CTAR1 domain caused a 3.1-fold
activation of the JNK1 pathway. Notably, the still functional
CTAR1 domain of LMP1(Y384G) induced JNK1 to a level of
2.5-fold. The LMP1(PQT→AAA/Y384G) double mutant was
included as a further null control which did not activate JNK1.
Next we asked what were the effects of JNK inhibition on
Rat1 cells expressing LMP1(PQT→AAA) or LMP1(Y384G).Fig. 4. Both CTAR1 and CTAR2 contribute to JNK1 activity in Rat1 cells. (A) JNK1
the indicated LMP1 constructs expressing LMP1Δ194–386 (no signaling domain), L
mutated), or LMP1(PQT→AAA/Y384G) (CTAR1/2 mutated). Subsequently, in vitro
HA-JNK1 activity detected as radioactive GST-c-Jun phosphorylation. Numbers gi
analysis of GST-c-Jun phosphorylation. Middle panel, immunoblot analysis of immun
unspecific band generated by the CS1–4 antibody. (B) LMP1 expression in Rat1 cell
by SP600125 retards proliferation of Rat1 cells stably expressing LMP1(PQT→AAA
Fig. 3B and can, thus, be compared directly. Data are mean values with standard deTo this end, we established Rat1 cell lines stably expressing
LMP1(PQT→AAA) or LMP1(Y384G) (Fig. 4B) and tested
the effects of SP600125 on proliferation of both cell lines
(Fig. 4C). Non-confluent monolayers of Rat1-PQT→AAA and
Rat1-Y384G cells showed similar proliferation rates which
were comparable to Rat1 wildtype and Rat1-LMP1 cells (see:
Fig. 3B). In accordance with previously reported results
(Mainou et al., 2005), Rat1-Y384G cells, as Rat1-LMP1 cells,
had overcome contact inhibition and continued to proliferate
also in confluent cell layers (data not shown and Fig. 4C, day 3
to 4). As expected from our JNK1 kinase assays, JNK inhibition
interfered with proliferation of both Rat1-PQT→AAA and
Rat1-Y384G cells, albeit to slightly different extends. SP600125
effects on Rat1-Y384G cells carrying a functional CTAR1
domain were more pronounced than on Rat1 cells expressing
LMP1 with a functional CTAR2 domain (Fig. 4C). Moreover,
activity of both CTAR domains seems to be required for a full
block of proliferation by SP600125 (compare Rat1→PQT-AAA
and Rat1-Y384G cells to Rat1-LMP1 cells, Fig. 3B). This result
suggested that CTAR1 and CTAR2 co-operate to fully establish
the JNK-dependent proliferation program of LMP1 in Rat1
cells.
Taken together, our data support the conclusion that Rat1
cells stably transfected with LMP1 and selected in vitro switch
to an LMP1-induced proliferation program to which the JNK
pathway contributes essential proliferative signals. This con-
clusion is corroborated by the fact that similar effects on Rat1-
LMP1 proliferation were obtained by two different methods of
JNK inhibition.kinase assays. Rat1 cells were electroporated with 6 μg of HA-JNK1 and 6 μg of
MP1 wildtype, LMP1(PQT→AAA) (CTAR1 mutated), LMP1(Y384G) (CTAR2
kinase assays were performed with immunoprecipitated HA-JNK1. Top panel,
ve x-fold induction levels of kinase activities as quantitated by phosphoimager
oprecipitated HA-JNK1. Bottom panel, LMP1 expression. The asterisk marks an
lines stably transfected with the indicated LMP1 constructs. (C) JNK inhibition
) or LMP1(Y384G). MTT assays were performed parallel to the assays shown in
viations of four experiments.
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of EBV-transformed human B-cells
The next step was to investigate the role of the LMP1-
induced JNK pathway in maintaining continuous proliferation
of EBV-transformed B-cells, the natural context of LMP1
function. EBV selectively infects human B-cells transforming
them into lymphoblastoid cell lines (LCLs). In LCLs, activity of
the JNK pathway is completely dependent on LMP1 expression
because no endogenous JNK1 and JNK2 activity is detectable
in the absence of LMP1 signaling in LCLs (Dirmeier et al.,
2005; Kieser et al., 1997; Kilger et al., 1998).
To study the effect of JNK inhibition, the widely-used
lymphoblastoid cell line 721 (Kavathas et al., 1980) was seeded
into 96-well-plates in the presence or absence of the JNK
inhibitor SP600125. Subsequently, MTTassays were performed
to monitor cell proliferation (Fig. 5A). The rates of MTT
conversion correlated with cell numbers (data not shown).
Inhibition of the LMP1-induced JNK pathway resulted in a
marked decrease in proliferation of 721 cells, as had already
been observed in Rat1-LMP1 cells (see above). This effect was
not due to a potential downregulation of LMP1 expression,
because LMP1 protein levels were not affected by SP600125
(Figs. 6A and B). A similar block of proliferation by SP600125
treatment was observed in a panel of established LCLs such as
EBV1.11 or 1852.4 as well as in LCLs freshly obtained byFig. 5. JNK inhibition interferes with proliferation and cell cycle progression of EBV-t
or 10 μM SP600125. Data are mean values with standard deviations of three experim
10 μM SP600125. After 2 days, the cells were stained with propidium iodide (PI) a
apoptosis. (C) JNK inhibition reduces the number of cells in S phase and increases G
incubated with BrdU for 2 h and total DNAwas stained with 7-AAD. Data acquisitio
experiments is shown. The table gives the percentages of cells detected within the indi
cells. Mean values with standard deviations of four experiments performed as describeinfection of human cord blood B-cells with B95.8 EBV (data
not shown).
Apoptosis assays were performed in 721 cells to exclude the
possibility that induction of programmed cell death was the
cause for the observed growth retardation after JNK inhibition
(Fig. 5B). The apoptosis rate was analyzed after 2 days of
incubation in the presence of the inhibitor. At this time point, the
SP600125-induced growth arrest was already in effect and
detectable (compare: Fig. 5A). In the absence of the JNK inhi-
bitor, continuously proliferating 721 cells showed a spontane-
ous apoptosis rate of 4.0%. Upon inhibition of the JNK pathway
the percentage of apoptotic cells in the 721 culture moderately
increased to 8.4%, an apoptosis rate which can be detected in
many normally proliferating cell lines and, thus, cannot explain
the massive effect of SP600125 on 721 proliferation.
Delayed cell cycle progression caused by JNK inhibition in
lymphoblastoid cell lines
A possible role of the JNK pathway in cell cycle progression
of LCLs was analyzed by bromodeoxyuridine (BrdU) incorpo-
ration assays. JNK inhibition in 721 cells by SP600125 caused a
marked decrease in cells in S phase (Figs. 5C and D). On
average, SP600125 reduced the percentage of 721 cells in S
phase from 36.5% to 15.9% (Fig. 5D). At the same time, the
percentage of G2/M phase cells increased significantly, indi-ransformed human B-cells. (A) MTTassays in the presence or absence of DMSO
ents. (B) Apoptosis detection. 721 cells were kept in the presence of DMSO or
nd Annexin-V-Cy5, and analyzed by flow cytometry. PI−/AnV+ cells indicate
2/M phase cells. 721 cells were treated as in panel B. After 2 days, the cells were
n was performed by flow cytometry. One representative experiment out of four
cated regions of the dot blots. (D) Cell cycle analysis upon JNK inhibition in 721
d in panel C (two-tailed Student's T-test ⁎⁎pb0.013, n=4; ⁎⁎⁎pb0.0014, n=4).
Fig. 6. JNK inhibition downregulates the expression of c-Jun and Cdc2 in lymphoblastoid cells. (A) Analysis of AP1 components. The LCL 721 was incubated in the
presence of DMSO (D) or 10 μM SP600125 (SP) for 2 days. Subsequently, protein expression was analyzed by immunoblotting with the indicated antibodies.
(B) Cdc2 but not CDK2 expression is controlled through JNK. 721 cells were treated as in panel A and subsequently analyzed by immunoblotting. (C) Specificity of
the JNK inhibitor SP600125 in LCLs. 721 cells were incubated in the presence of 0.5‰ DMSO or 10 μM SP600125 for the indicated times. Activity of LMP1-
regulated pathways was detected by phospho-specific antibodies. (D) The JNK inhibitor AS601245 blocks proliferation of 721 cells. MTT assays in the presence of
5 μM AS601245 (AS) or 0.25‰ DMSO (D). (E) JNK inhibition by AS601245 reduces c-Jun and Cdc2 expression in 721 cells. The cells were incubated in the
presence of DMSO (D) or 5 μM AS601245 (AS) for 2 days. Protein expression was analyzed by immunoblotting with the indicated antibodies.
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delayed upon JNK inhibition (Figs. 5C and D). Because JNK
activation in LCLs is mediated by LMP1 (Dirmeier et al., 2005;
Kieser et al., 1997; Kilger et al., 1998), we concluded that
LMP1-induced JNK activity is required for progression of
LCLs through the cell cycle.
LMP1-induced JNK signaling controls c-Jun and Cdc2
expression in LCLs
Previously, we have identified direct LMP1 target genes in
oligonucleotide arrays as being upregulated within 30 min after
activation of LMP1 signaling (Dirmeier et al., 2005). The direct
LMP1 target gene c-jun was a prime candidate to mediate
LMP1-induced JNK effects on the cell cycle because c-Jun is a
JNK substrate and has been described as a positive cell cycle
regulator (Mechta-Grigoriou et al., 2001; Shaulian and Karin,
2002). Therefore, we examined whether JNK inhibition had
an effect on c-Jun expression in 721 cells. Upon incubation
with SP600125 for 3 days, c-Jun levels were strongly reduced
(Fig. 6A). Moreover, we observed a downregulation of c-Jun
expression as early as 3 h after incubation of 721 cells with
SP600125 (Fig. 6C). This negative effect of JNK inhibition on c-
Jun protein levels can be explained by the fact that c-Jun controls
its own expression in a positive autoregulatory loop (Vogt,
2001). Thus, a decreased transcriptional activity of c-Jun caused
by its reduced phosphorylation through inhibition of the LMP1-
induced JNK pathway is expected to lower c-Jun expression in
LCLs. In addition to c-Jun, JunB expression was also down-regulated by JNK inhibition in 721 cells. In contrast, LMP1, JunD
and c-Fos levels remained unaffected by SP600125 demonstra-
ting the specificity of the observed effects on c-Jun (Fig. 6A).
The JNK/c-Jun pathway has been shown to control G2/M
transition by activating transcription of the essential G2/M cell
cycle kinase Cdc2 (also known as CDK1) through an AP1 site
in the Cdc2 promoter (Wada et al., 2004). Therefore, we tested
whether JNK inhibition had an effect on Cdc2 expression in
LCLs (Fig. 6B). Indeed, reduced levels of Cdc2 protein, but not
of the G1/S cell cycle kinase CDK2 (cyclin-dependent kinase
2), were detected in SP600125-treated 721 cells. JNK inhibition
reduced the level of Cdc2 protein to about 40% of mock-treated
cells, as determined by quantification of the Cdc2 signals. A
similar reduction of Cdc2 expression was observed after the
knockout of MKK7 resulting in defective JNK/c-Jun signaling
and, thus, G2/M phase progression (Wada et al., 2004). In
summary, our results demonstrate that LMP1 controls c-Jun and
Cdc2 expression through JNK.
To exclude effects of SP600125 on LMP1-induced pathways
other than the JNK/c-Jun pathway, 721 cells were incubated for
different time periods in the presence or absence of 10 μM
SP600125. Activities of the NF-κB, PI3-kinase/Akt, p38
MAPK, and JNK/c-Jun pathways were determined with the
help of phospho-specific antibodies (Fig. 6C). With the excep-
tion of JNK/c-Jun, no other LMP1 signaling pathway was
downregulated by SP600125 treatment in LCLs, demonstrating
SP600125 specificity for the LMP1-induced JNK pathway.
The SP600125 inhibitor is an anthrapyrazolone derivative
(Bennett et al., 2001). Recently, a novel inhibitor with high
253H. Kutz et al. / Virology 371 (2008) 246–256selectivity for JNK has been described, AS601245, which
belongs to a new class of benzothiazole acetonitrile derivatives
and, thus, proved to be a structurally unique JNK inhibitor
(Gaillard et al., 2005). To test if AS601245 reproduced the
effects of JNK inhibition by SP601245 on LCL proliferation,
MTT assays were performed in 721 cells in the presence or
absence of the AS601245 inhibitor. Indeed, 5 μM AS601245
almost completely blocked proliferation of 721 cells, confirm-
ing our results obtained with the SP600125 inhibitor (Fig. 6D).
As with JNK inhibition by SP600125, c-Jun and Cdc2, but not
CDK2, protein levels were strongly reduced by the AS601245
inhibitor in the LCL 721 (Fig. 6E). Because both JNK inhibitors
are structurally not related but induced similar effects in 721
cells, we concluded that the observed effects were in fact JNK-
specific and not due to unspecific side effects of SP600125
(Huang et al., 2006).
SP600125 causes reduced tumor growth of EBV-transformed
human B-cells in SCID mice
Because of the robust in vitro effects of JNK inhibition on
proliferation of EBV-transformed human B-cells, we tested
whether SP600125 might reduce tumor growth of LCLs inFig. 7. The JNK inhibitor SP600125 retards tumor growth of lymphoblastoid cells
in SCID mice. (A) Representative examples of tumors removed from inhibitor- or
vehicle-treated animals at day 21 post transplantation of the LCL 721. Scale: cm.
(B) Bodyweight and tumormass plotted for eachmouse. Horizontal bars represent
means of total body weight (vehicle group (V) 20.0±0.3 g; inhibitor group (SP)
20.4±0.7 g) and tumor mass (vehicle group 1.14±0.18 g; inhibitor group 0.58±
0.16 g). The difference between the tumor mass of vehicle and inhibitor mice was
statistically significant (two-tailed Student's T-test pb0.05, n=5).xenotransplanted SCID mice, which is a standard model for
EBV-associated lymphoproliferative disease (Dirmeier et al.,
2003). Ten SCID mice were subcutaneously injected with
2×107 721 cells. Starting from day 2, the mice were treated
with SP600125 or the vehicle alone for 20 days. SP600125 had
no effect on total body weight and no obvious behavioural
changes were observed in the SP600125-treated mice. Solid
tumors developed at the site of injection and no metastases were
detected in spleen, liver, lungs, thymus area or lymph nodes. All
tumors expressed similar levels of LMP1, irrespective of the
tumor size and SP600125 treatment (data not shown). LCL
tumor growth was significantly retarded by the JNK inhibitor
(Figs. 7A and B). Average tumor size was reduced by about
50% from 1.14±0.18 g in the control mice to 0.58±0.16 g in the
inhibitor-treated animals. These results underscored the impor-
tance of the JNK pathway for growth transformation by LMP1
also in vivo and demonstrated that the JNK pathway might serve
as a target to counteract EBV-associated malignancies.
Discussion
In this work we showed that the JNK pathway contributes
critical proliferative signals to the transforming potential of
LMP1. Interference with LMP1-induced JNK signaling caused
a prolongation of the cell cycle, detected as a strongly reduced
number of LCLs in S phase. We provided evidence that the
JNK-mediated LMP1 signals are required for efficient G2/M
progression of LCLs because inhibition of the LMP1-induced
JNK pathway resulted in an increased number of cells in G2/M
phase. The JNK pathway couples LMP1 to the regulation of
Cdc2 expression, the essential G2/M cell cycle kinase, most
probably mediated through c-Jun/AP1. Thus, our results estab-
lish a clear functional link between LMP1 signaling and G2/M
phase progression of EBV-transformed cells. Interestingly, en-
hanced LMP1 expression has previously been observed to cause
an accumulation of cells at the G2/M phase of the cell cycle in
several B cell lines, suggesting that hyperactive LMP1 signaling
might activate a G2/M cell cycle checkpoint (Floettmann et al.,
1996). Taken together, these data indicate that a balanced LMP1
expression is required to ensure proper G2/M progression. In
addition to the JNK pathway, also the CTAR1-triggered PI3-
kinase pathway might contribute to LMP1-driven cell cycle
progression because this pathway can activate a gene expression
network controlling G1 phase (Dawson et al., 2003; Everly et
al., 2004; Liang and Slingerland, 2003). Thus, growth trans-
formation by LMP1 is likely to be achieved by simultaneous
activation of proliferative signals generated by the JNK and
PI3-kinase pathways together with anti-apoptotic signaling
mediated by NF-κB.
Reduced proliferation can be due to a defect in cell cycle
progression, induction of apoptosis, or both. Here, we showed
that EBV-transformed lymphoblastoid cells, which depend on
LMP1 activity for their proliferation, arrest in the cell cycle but
do not significantly die from apoptosis upon inhibition of the
LMP1-induced JNK pathway. In contrast, defective JNK
signaling in EBV-negative B-lymphoma cells caused a high
apoptosis rate as well as a defect in cell cycle progression
254 H. Kutz et al. / Virology 371 (2008) 246–256(Gururajan et al., 2005). Likely, LMP1-induced anti-apoptotic
signaling rescued LCLs from apoptosis associated with cell
cycle arrest upon JNK inhibition. In murine B-lymphoma cells,
CD40 activity was sufficient to overcome the proliferation
arrest induced by JNK inhibition (Gururajan et al., 2005). In
contrast, we showed here that LMP1 signaling, the viral mimic
of CD40, was dependent on JNK to drive LCL proliferation,
supporting previous observations that EBV-transformed B-cells
proliferate under a different proliferation program than B-
lymphoma cells (Polack et al., 1996).
JNK inhibition strongly retarded proliferation of Rat1-LMP1
cells, whereas JNK activity was not required for continuous
proliferation of Rat1 wildtype cells. This finding suggests that
stable expression of LMP1 and subsequent selection reprograms
Rat1 cells, switching them to an LMP1-type proliferation pro-
gram which is dependent on JNK signals and differs from the
program of parental Rat1 cells. Accordingly, the levels of
phosphorylated c-Jun, the primary target of the JNK pathway,
were highly elevated in LMP1-transformed Rat1 cells. In con-
trast, Rat1 wildtype cells exhibit very low levels of endogenous
JNK activity and phosphorylated c-Jun (Sunters et al., 2006;
Watson et al., 1998) (see: Fig. 3A). Controversial results have
been published regarding the role of the CTAR2 domain in Rat1
transformation by LMP1. One study has demonstrated that
LMP1Δ242–386, encompassing a functional CTAR1 domain
but lacking CTAR2, did not transform Rat1 cells in focus
forming assays (Moorthy and Thorley-Lawson, 1993). More-
over, deletion of the C-terminal amino acids 364 to 386 of
CTAR2 was sufficient to abrogate LMP1's transforming
potential in Rat1 cells (Moorthy and Thorley-Lawson, 1993).
Supporting these results, mutation of Y384 and Y385 of CTAR2
severely affected LMP1's oncogenic potential in Rat1 cells in
vitro and in vivo (He et al., 2000). In contrast, a recent study
suggested that expression of LMP1(1–231) lacking CTAR2 still
transforms Rat1 cells (Mainou et al., 2005). Rat1-Y384G cells
established in the present work also formed colonies in soft agar
which were, however, significantly smaller than Rat1-LMP1
colonies (data not shown). Probably, these discrepancies reflect
differences in Rat1 laboratory subclones. Our data finally sug-
gest a co-operative role for CTAR1 and CTAR2 in establishing
the JNK-dependent proliferation program of LMP1 in Rat1 cells.
We demonstrated that inhibition of the JNK pathway by the
JNK-specific inhibitor SP600125 resulted in reduced tumor
growth of LCLs in SCID mice. Notably, treatment of SCID
mice with this inhibitor did not result in systemic toxicity but
induced specific effects on the tumor cells. According to our in
vitro results, it is possible that the effect of SP600125 is also
reversible in vivo. Therefore, inhibition of the JNK pathway
alone might not be sufficient to fully eradicate LMP1-ex-
pressing tumors in patients. We envision the following
situations in which JNK inhibitor effects could be nonetheless
beneficial for EBV-associated tumor therapy. Combined
treatment with additional inhibitors blocking anti-apoptotic or
transforming signaling pathways might result in synergistic
effects leading to enhanced tumor cell death. Alternatively, JNK
inhibitors could be useful to reduce overall tumor load sup-
porting tumor-specific immune therapy, for instance of PTLDpatients. It is also tempting to speculate that tumor cells affected
by JNK inhibition might be more susceptible to some classes of
cytotoxic drugs in vivo. In summary, our experiments show that
the JNK pathway could serve as a promising target to counteract
EBV-associated malignancies expressing LMP1, such as post-
transplant lymphoproliferative disorders, Hodgkin's lympho-
ma, or nasopharyngeal carcinoma.
Materials and methods
Plasmids
pSV-LMP1, pSV-LMP1Δ194–386 , pSV-LMP1
(PQT→AAA), pSV-LMP1(Y384G), pSV-LMP1(PQT→AAA/
Y384G), pSEK1-AL/EE-CMV, and the AP1 luciferase reporter
plasmid pRTU14 have been described (Kieser et al., 1997,
1999). To clone pRK5-HA-JNK1 and pRK5-HA-JNK2, human
JNK1α1 and JNK2α2 cDNAs were N-terminally fused with a
hemagglutinin (HA)-tag by PCR and cloned into pRK5. D169A
point mutations were inserted by overlap-extension-PCR.
Cell culture methods and reporter assays
Rat1 fibroblasts stably expressing LMP1 and LMP1 mutants
were generated by transfection of Rat1 cells with pSV-LMP1
expression vectors (see above) and subsequent selection in the
presence of 250 μg ml−1 hygromycin B. Rat1 cells were cultured
in DMEM full medium (Invitrogen) supplementedwith 10% fetal
calf serum (FCS, Biochrom). HEK293 human kidney cells and
lymphoblastoid cells were grown in RPMI full medium sup-
plemented with 10% FCS. Phoenix cells were grown in DMEM
full medium containing 10% FCS and 20 mM HEPES. For soft
agar assays, cells were seeded in 0.4% noble agar (Sigma) in
DMEM full medium onto a 0.5% bottom agar layer in the
presence of 20 μM SP600125 or DMSO as indicated. Rat1 and
HEK293 cells were transfected using the Lipofectamine reagent
(Invitrogen). 3-(4,5-dimethylthiazol-2-yl)-2,2,5-diphenyl tetrazo-
lium bromide (MTT) assays were performed as described (Kilger
et al., 1998). For reporter and kinase assays, 1×107 Rat1 cells
were electroporatedwith the indicatedDNAs at 240Vand 975 μF
in a BioRad Gene Pulser II. AP1 reporter assays were performed
as described using the pRTU14 reporter plasmid (Kieser et al.,
1999). SP600125 (Axxora) and AS601245 (Calbiochem) were
dissolved in DMSO and stored in aliquots at −20 °C.
Immunocomplex kinase assays and antibodies
Immunocomplex kinase assays were performed as described
using the rat anti-HA antibody 3F10 (Roche) to precipitate HA-
JNK (Schultheiss et al., 2001). The following primary antibodies
were used for immunoblotting: α-Tubulin (B-5-1-2); Actin
(I19), c-Fos (H125), I-κB-α (C21), JunB (N17), JunD (329),
JNK1 (C17), JNK2 (FL) (all: Santa Cruz Biotech.), LMP1
(CS1–4) (Dako), Akt, phospho-Akt (Thr308), Cdc2, phos-
phoso-I-κB-α (Ser32), c-Jun, phospho-c-Jun (Ser63), p38
MAPK, phospho-p38 MAPK (Thr180/Tyr182) (all: Cell
Signaling Technology), and CDK2 (Ab4) (Neomarkers).
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3054-HA-JNK1(D169A) was generated by inserting HA-
JNK1(D169A) into the NotI cloning site of the retroviral vector
SF91-IRES-GFP-WPRE (kind gift from Christopher Baum)
(Schwieger et al., 2002). For virus production, 3×106 Phoenix
cells were transfected in a 10 cm dish with 5 μg of retroviral
vector together with 10 μg of a gag–pol expression vector and
2 μg pEcoEnv expressing ecotropic env (Morita et al., 2000)
using calcium phosphate transfection in the presence of 25 μM
chloroquine. 6 h post transfection, the cells were incubated for
another 72 h in DMEM full medium supplemented with 20 mM
HEPES (pH 7.9) for virus production. Rat1 and Rat1-LMP1
cells were infected with virus supernatants in the presence of
100 μg ml−1 polybrene.
Apoptosis assays
1×105 lymphoblastoid cells were kept in the presence of
0.5‰ DMSO or 10 μM SP600125 for 48 h. Subsequently, the
cells were incubated with 0.5 μg ml−1 propidium iodide (PI) and
Cy5-labeled Annexin-V (Apoptosis Detection Kit, BioVision)
according to the manufacturer's protocol. The cells were
analyzed for PI and Annexin-V-Cy5 staining by flow cytometry
in a FACSCalibur flow cytometer (BectonDickinson). Data were
analyzed using the Cellquest Pro software (Becton Dickinson).
Cell cycle analysis
Cell cycle analysis by bromodeoxyuridine (BrdU) staining
was performed using the FITC-BrdU Flow kit (BD Pharmin-
gen). The cells were incubated with 10 μMBrdU for 2 h to label
newly synthesized DNAwhich was detected by a FITC-coupled
anti-BrdU antibody. Total DNA was stained by the fluorescent
dye 7-amino-actinomycin D (7-AAD). Detection of BrdU and 7-
AAD staining by flow cytometry and subsequent data analysis
was performed in a FACSCalibur flow cytometer according to
the manufacturer's instructions.
In vivo studies
C.B-17 SCID mice (Taconic, Denmark) were kept under
pathogen-free conditions. Procedures were reviewed and
approved by the Governmental Animal Care and Use Commit-
tee. Ten female mice (8- to 12-week-old; 18 to 22 g body weight)
were set up in two cohorts with five animals per cage. At day 0,
mice were administered subcutaneously 2×107 721 cells in the
left flank. From day 2, mice were daily injected i.p. either with
60 mg kg−1 body weight SP600125 or the vehicle (DMSO/PBS)
for 20 days. Animals were sacrificed on day 21 and dissected
immediately. Total tumor mass was removed and weighed.
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